Pharsight Corporation Announces Eli Lilly and Company's Acquisition of Modeling and Analysis Software

Eli Lilly and Company, a global research-based pharmaceutical corporation, has purchased Pharsight's modeling and analysis software to aid in their research and development. The software, WinNonlin-Pro, is being deployed in targeted disease areas such as central nervous system and related diseases, endocrine diseases, infectious diseases, cancer, and cardiovascular diseases. This acquisition is expected to aid in Lilly's clinical development strategy by providing computer tools that enhance the efficiency and quality of clinical trials.

Key Takeaways:

• Eli Lilly and Company, a global research-based pharmaceutical corporation, has acquired Pharsight's modeling and analysis software, WinNonlin-Pro, to aid in their research and development.
• The software is being deployed in targeted disease areas such as central nervous system and related diseases, endocrine diseases, infectious diseases, cancer, and cardiovascular diseases.
• This acquisition is expected to aid in Lilly's clinical development strategy by providing computer tools that enhance the efficiency and quality of clinical trials.
• Pharsight Corporation is a leader in computer-assisted trial design (CATD) software and services.
• Pharsight's modeling and analysis software will be used to aid in the development of new drugs and identify potential failures early in the clinical trial process.
• The clinical development process involves an average of 64 trials before a new drug is submitted for review to the U.S. Food and Drug Administration (FDA), yet up to 50 percent of these trials fail to provide conclusive or useful results.
• It takes approximately 15 years and $500 million to bring a new drug to market, and clinical trials account for approximately one-half of the time and one-third of the cost required.

Statistics:

• 64 trials are required on average before a new drug is submitted for review to the U.S. Food and Drug Administration (FDA).
• Up to 50 percent of clinical trials fail to provide conclusive or useful results.
• It takes approximately 15 years and $500 million to bring a new drug to market.
• Clinical trials account for approximately one-half of the time and one-third of the cost required.
• Pharsight's WinNonlin-Pro software is being used in targeted disease areas such as central nervous system and related diseases, endocrine diseases, infectious diseases, cancer, and cardiovascular diseases.

Sources:

• Business Wire - July 21, 1998
• Eli Lilly and Company Announces Purchase of Pharsight's Software to Aid Research and Development
• Pharsight Corporation Announces Eli Lilly and Company's Acquisition of Modeling and Analysis Software
• Clinical Pharmacology/Pharmacokinetic division of Eli Lilly and Company
• Pharsight Corporation
• Cognex Corporation - July 5, 1998